BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

374 related articles for article (PubMed ID: 26060018)

  • 1. Androgen Receptor Splice Variants Dimerize to Transactivate Target Genes.
    Xu D; Zhan Y; Qi Y; Cao B; Bai S; Xu W; Gambhir SS; Lee P; Sartor O; Flemington EK; Zhang H; Hu CD; Dong Y
    Cancer Res; 2015 Sep; 75(17):3663-71. PubMed ID: 26060018
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Interplay between Cytoplasmic and Nuclear Androgen Receptor Splice Variants Mediates Castration Resistance.
    Zhan Y; Zhang G; Wang X; Qi Y; Bai S; Li D; Ma T; Sartor O; Flemington EK; Zhang H; Lee P; Dong Y
    Mol Cancer Res; 2017 Jan; 15(1):59-68. PubMed ID: 27671337
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Androgen receptor splice variants activating the full-length receptor in mediating resistance to androgen-directed therapy.
    Cao B; Qi Y; Zhang G; Xu D; Zhan Y; Alvarez X; Guo Z; Fu X; Plymate SR; Sartor O; Zhang H; Dong Y
    Oncotarget; 2014 Mar; 5(6):1646-56. PubMed ID: 24722067
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Distinct transcriptional programs mediated by the ligand-dependent full-length androgen receptor and its splice variants in castration-resistant prostate cancer.
    Hu R; Lu C; Mostaghel EA; Yegnasubramanian S; Gurel M; Tannahill C; Edwards J; Isaacs WB; Nelson PS; Bluemn E; Plymate SR; Luo J
    Cancer Res; 2012 Jul; 72(14):3457-62. PubMed ID: 22710436
    [TBL] [Abstract][Full Text] [Related]  

  • 5. DBC1 promotes castration-resistant prostate cancer by positively regulating DNA binding and stability of AR-V7.
    Moon SJ; Jeong BC; Kim HJ; Lim JE; Kwon GY; Kim JH
    Oncogene; 2018 Mar; 37(10):1326-1339. PubMed ID: 29249800
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Constitutively active androgen receptor splice variants expressed in castration-resistant prostate cancer require full-length androgen receptor.
    Watson PA; Chen YF; Balbas MD; Wongvipat J; Socci ND; Viale A; Kim K; Sawyers CL
    Proc Natl Acad Sci U S A; 2010 Sep; 107(39):16759-65. PubMed ID: 20823238
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Androgen receptors in hormone-dependent and castration-resistant prostate cancer.
    Shafi AA; Yen AE; Weigel NL
    Pharmacol Ther; 2013 Dec; 140(3):223-38. PubMed ID: 23859952
    [TBL] [Abstract][Full Text] [Related]  

  • 8. ZFX Mediates Non-canonical Oncogenic Functions of the Androgen Receptor Splice Variant 7 in Castrate-Resistant Prostate Cancer.
    Cai L; Tsai YH; Wang P; Wang J; Li D; Fan H; Zhao Y; Bareja R; Lu R; Wilson EM; Sboner A; Whang YE; Zheng D; Parker JS; Earp HS; Wang GG
    Mol Cell; 2018 Oct; 72(2):341-354.e6. PubMed ID: 30270106
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Androgen receptor splice variants drive castration-resistant prostate cancer metastasis by activating distinct transcriptional programs.
    Han D; Labaf M; Zhao Y; Owiredu J; Zhang S; Patel K; Venkataramani K; Steinfeld JS; Han W; Li M; Liu M; Wang Z; Besschetnova A; Patalano S; Mulhearn MJ; Macoska JA; Yuan X; Balk SP; Nelson PS; Plymate SR; Gao S; Siegfried KR; Liu R; Stangis MM; Foxa G; Czernik PJ; Williams BO; Zarringhalam K; Li X; Cai C
    J Clin Invest; 2024 Apr; 134(11):. PubMed ID: 38687617
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Androgen receptor variant-driven prostate cancer II: advances in laboratory investigations.
    Lu C; Brown LC; Antonarakis ES; Armstrong AJ; Luo J
    Prostate Cancer Prostatic Dis; 2020 Sep; 23(3):381-397. PubMed ID: 32139878
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Calpain and AR-V7: Two potential therapeutic targets to overcome acquired docetaxel resistance in castration-resistant prostate cancer cells.
    Liu L; Lou N; Li X; Xu G; Ruan H; Xiao W; Qiu B; Bao L; Yuan C; Huang X; Wang K; Cao Q; Chen K; Yang H; Zhang X
    Oncol Rep; 2017 Jun; 37(6):3651-3659. PubMed ID: 28498452
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Constitutively active androgen receptor splice variants AR-V3, AR-V7 and AR-V9 are co-expressed in castration-resistant prostate cancer metastases.
    Kallio HML; Hieta R; Latonen L; Brofeldt A; Annala M; Kivinummi K; Tammela TL; Nykter M; Isaacs WB; Lilja HG; Bova GS; Visakorpi T
    Br J Cancer; 2018 Aug; 119(3):347-356. PubMed ID: 29988112
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Histone lysine demethylase KDM4B regulates the alternative splicing of the androgen receptor in response to androgen deprivation.
    Duan L; Chen Z; Lu J; Liang Y; Wang M; Roggero CM; Zhang QJ; Gao J; Fang Y; Cao J; Lu J; Zhao H; Dang A; Pong RC; Hernandez E; Chang CM; Hoang DT; Ahn JM; Xiao G; Wang RT; Yu KJ; Kapur P; Rizo J; Hsieh JT; Luo J; Liu ZP
    Nucleic Acids Res; 2019 Dec; 47(22):11623-11636. PubMed ID: 31647098
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Androgen receptor splice variants circumvent AR blockade by microtubule-targeting agents.
    Zhang G; Liu X; Li J; Ledet E; Alvarez X; Qi Y; Fu X; Sartor O; Dong Y; Zhang H
    Oncotarget; 2015 Sep; 6(27):23358-71. PubMed ID: 26160840
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Analytical Validation of Androgen Receptor Splice Variant 7 Detection in a Clinical Laboratory Improvement Amendments (CLIA) Laboratory Setting.
    Lokhandwala PM; Riel SL; Haley L; Lu C; Chen Y; Silberstein J; Zhu Y; Zheng G; Lin MT; Gocke CD; Partin AW; Antonarakis ES; Luo J; Eshleman JR
    J Mol Diagn; 2017 Jan; 19(1):115-125. PubMed ID: 27916435
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Expression of androgen receptor splice variants in prostate cancer bone metastases is associated with castration-resistance and short survival.
    Hörnberg E; Ylitalo EB; Crnalic S; Antti H; Stattin P; Widmark A; Bergh A; Wikström P
    PLoS One; 2011 Apr; 6(4):e19059. PubMed ID: 21552559
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Isoform-specific Activities of Androgen Receptor and its Splice Variants in Prostate Cancer Cells.
    Nagandla H; Robertson MJ; Putluri V; Putluri N; Coarfa C; Weigel NL
    Endocrinology; 2021 Mar; 162(3):. PubMed ID: 33300995
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Are androgen receptor variants a substitute for the full-length receptor?
    Lu J; Van der Steen T; Tindall DJ
    Nat Rev Urol; 2015 Mar; 12(3):137-44. PubMed ID: 25666893
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Regulation of the transcriptional coactivator FHL2 licenses activation of the androgen receptor in castrate-resistant prostate cancer.
    McGrath MJ; Binge LC; Sriratana A; Wang H; Robinson PA; Pook D; Fedele CG; Brown S; Dyson JM; Cottle DL; Cowling BS; Niranjan B; Risbridger GP; Mitchell CA
    Cancer Res; 2013 Aug; 73(16):5066-79. PubMed ID: 23801747
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A positive role of c-Myc in regulating androgen receptor and its splice variants in prostate cancer.
    Bai S; Cao S; Jin L; Kobelski M; Schouest B; Wang X; Ungerleider N; Baddoo M; Zhang W; Corey E; Vessella RL; Dong X; Zhang K; Yu X; Flemington EK; Dong Y
    Oncogene; 2019 Jun; 38(25):4977-4989. PubMed ID: 30820039
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 19.